BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lehtola E, Haapamäki J, Färkkilä MA. Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up. Scand J Gastroenterol 2016;51:1476-81. [PMID: 27686143 DOI: 10.1080/00365521.2016.1218539] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Ylisaukko-Oja T, Puttonen M, Jokelainen J, Koivusalo M, Tamminen K, Torvinen S, Voutilainen M. Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice. Scand J Gastroenterol 2021;:1-9. [PMID: 34927504 DOI: 10.1080/00365521.2021.2014950] [Reference Citation Analysis]
2 Sochal M, Krzywdzińska M, Gabryelska A, Talar-Wojnarowska R, Małecka-Panas E. Efficiency and safety of one-year anti-TNF-α treatment in Crohn's disease: a Polish single-centre experience. Prz Gastroenterol 2020;15:156-60. [PMID: 32550949 DOI: 10.5114/pg.2019.90079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Krusiński A, Grzywa-Celińska A, Szewczyk K, Grzycka-Kowalczyk L, Emeryk-Maksymiuk J, Milanowski J. Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents. Int J Inflam 2021;2021:6284987. [PMID: 33489084 DOI: 10.1155/2021/6284987] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lee Y, Choo J, Kim SJ, Heo G, Pothoulakis C, Kim YH, Im E. Analysis of endogenous lipids during intestinal wound healing. PLoS One 2017;12:e0183028. [PMID: 28800645 DOI: 10.1371/journal.pone.0183028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
5 Villanacci V, Cadei M, Lanzarotto F, Ricci C, Antonelli E, Cannatelli R, Gulotta T, Fontana L, Pasquali V, Sigala S, Salviato T, Nascimbeni R, Bassotti G. Localization of TNF alpha in ileocolonic biopsies of patients with inflammatory bowel disease. Ann Diagn Pathol 2019;38:20-5. [PMID: 30388432 DOI: 10.1016/j.anndiagpath.2018.10.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Shivaji UN, Bazarova A, Critchlow T, Smith SCL, Nardone OM, Love M, Davis J, Ghosh S, Iacucci M. Clinical outcomes, predictors of prognosis and health economics consequences in IBD patients after discontinuation of the first biological therapy. Therap Adv Gastroenterol 2020;13:1756284820981216. [PMID: 34104206 DOI: 10.1177/1756284820981216] [Reference Citation Analysis]
7 Larsen L, Drewes AM, Broberg MCH, Fallingborg J, Jacobsen BA, Jensen TB, Jess T. Changing Infliximab Prescription Patterns in Inflammatory Bowel Disease: A Population-Based Cohort Study, 1999-2014. Inflamm Bowel Dis 2018;24:433-9. [PMID: 29361095 DOI: 10.1093/ibd/izx038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]